Stevanato Group Introduces New Proprietary Pen Injector Platform

Stevanato Group S.p.A., a global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, has introduced Deora, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.

Deora is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL.

“With Deora, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. “We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up.”

The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing.

“Deora further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” Monico added.

Customers can now choose from different hand-held device platforms (Alina, Aidaptus, and Deora) to address a broad range of therapeutic needs.